Business Context and Reporting Period
This Form 6-K is a transaction notification filed by GlaxoSmithKline plc for the period ending December 20, 2018. The filing reports a specific transaction involving a Person Discharging Managerial Responsibilities (PDMR) under the GlaxoSmithKline Deferred Investment Award plan.
Key Financial Metrics
The filing does not provide consolidated revenue, profit, cash flow, margins, debt, or liquidity metrics for the company. It details a single executive compensation transaction:
- Transaction Type: Cash payout following the vesting of an award.
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Volume: 3,231.899 notional Ordinary Shares.
- Price: £14.8000 per share.
- Value: £47,832.11 (gross, less applicable tax withholding).
- Transaction Date: December 17, 2018.
Material Changes
The filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It solely documents the settlement of a deferred investment award for Mr. R Simard, President of Pharma Supply Chain.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of an insider transaction.
Key Facts for Investor Verification
- Verify the vesting schedule and terms of the GlaxoSmithKline Deferred Investment Award plan referenced in the transaction.
- Confirm the tax withholding implications for the reported cash payout of £47,832.11.
- Note that this filing does not reflect the company's overall financial performance for the quarter or year.